Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

A Retrospective Cohort Analysis of Minimal Residual Disease (MRD) across Therapy in FLT3 Acute Myeloid Leukemia (AML)

Arshia Arora, Hua-Ling Tsai, Venkata Preetam Sandeep Kaduluri, Mark J. Levis, Alexander J. Ambinder

Blood (2024) 144 (Supplement 1): 6171.

https://doi.org/10.1182/blood-2024-211081

Published: 2024

Journal Articles

High Molecular Risk Mutations (HMR) Drive Progression of CALR -mutated Myeloproliferative Neoplasm (MPN)

Resham Mawalkar, Hua-Ling Tsai, Terra Marie M Jouaneh, Shivam Patel, Christopher Gocke, Eitan Halper-Stromberg, Rena R. Xian, K. C. Rappazzo, Evan M. Braunstein, Alison R. Moliterno, Tania Jain

Blood (2024) 144 (Supplement 1): 3173.

https://doi.org/10.1182/blood-2024-194860

Published: 2024

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

Favorable Outcomes for High-Risk MDS and Oligoblastic AML with MDS-Related Changes with Reduced Intensity Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Ilias Sinanidis, Michael Jamie Hochman, Hua-Ling Tsai, Michael P Randall, Brandon Bonilla, Ravi Varadhan, Alexander Joseph Ambinder, Amy E. DeZern, Theodoros Karantanos

Blood (2023) 142 (Supplement 1): 3229.

https://doi.org/10.1182/blood-2023-187247

Published: 2023

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

Allogeneic Blood or Marrow Transplantation (alloBMT) Using Haploidentical Grandchildren Donors and Post-Transplant Cyclophosphamide (PTCy) -Based Gvhd Prophylaxis

Yosra M. Aljawai, Hua-Ling Tsai, Ravi Varadhan, Richard J. Jones, Philip H. Imus

Blood (2022) 140 (Supplement 1): 4721–4722.

https://doi.org/10.1182/blood-2022-169028

Published: 2022

Journal Articles

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Blood (2022) 140 (Supplement 1): 7731–7733.

https://doi.org/10.1182/blood-2022-157985

Published: 2022

Journal Articles

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

Shannon R. McCurdy, Vedran Radojcic, Hua-Ling Tsai, Ante Vulic, Elizabeth Thompson, Sanja Ivcevic, Christopher G. Kanakry, Jonathan D. Powell, Brian Lohman, Djamilatou Adom, Sophie Paczesny, Kenneth R. Cooke, Richard J. Jones, Ravi Varadhan, Heather J. Symons, Leo Luznik

Blood (2022) 139 (4): 608–623.

https://doi.org/10.1182/blood.2021013054

Published: 2022

Includes: Supplemental data

Journal Articles

The Presence of SETBP1 , RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents

Theodoros Karantanos, Hua-Ling Tsai, Mark Levis, Ravi Varadhan, Richard J. Jones, Tania Jain

Blood (2021) 138 (Supplement 1): 1520.

https://doi.org/10.1182/blood-2021-151624

Published: 2021

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141294

Published: 2020

Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-141264

Published: 2020

Journal Articles

Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN)

Theodoros Karantanos, MDPhD, Hua-Ling Tsai, ScM, Lukasz P. Gondek, MDPhD, Mark Levis, MD PhD, Margaret M. Showel, MD, Amy E. DeZern, MD, Ivana Gojo, MD, Ravi Varadhan, PhD, Richard J. Jones, MD, Tania Jain, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-138671

Published: 2020

Journal Articles

The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient

Clio E Franklin, MBBS, BSc, MRCP, Margaret M. Showel, MD, Hua-Ling Tsai, ScM, Ravi Varadhan, PhD, Shannon R. McCurdy, MD, Douglas E. Gladstone, MD, Richard J. Jones, MD, Amy E. DeZern, MD

Blood (2017) 130 (Supplement 1): 849.

https://doi.org/10.1182/blood.V130.Suppl_1.849.849

Published: 2017

Journal Articles

Grade II Acute Gvhd Improves Progression-Free Survival after Myeloablative HLA-Matched Bone Marrow Transplant with Posttransplantation Cyclophosphamide

Shannon R. McCurdy, MD, Christopher G. Kanakry, MD, Hua-Ling Tsai, ScM, Javier Bolaños-Meade, MD, Ephraim J. Fuchs, MD MBA, Gary Rosner, ScD, Richard J. Jones, MD, Leo Luznik, MD

Blood (2017) 130 (Supplement 1): 216.

https://doi.org/10.1182/blood.V130.Suppl_1.216.216

Published: 2017

Journal Articles

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Blood (2015) 125 (19): 3024–3031.

https://doi.org/10.1182/blood-2015-01-623991

Published: 2015

Includes: Supplemental data

Journal Articles

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Blood (2014) 124 (25): 3817–3827.

https://doi.org/10.1182/blood-2014-07-587477

Published: 2014

Includes: Supplemental data

Journal Articles

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Shannon R. McCurdy, Jennifer A. Kanakry, Margaret M. Showel, Hua-Ling Tsai, Javier Bolaños-Meade, Christopher G. Kanakry, Douglas E. Gladstone, Leo Luznik, Carol Ann Huff, Lode J. Swinnen, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs, Yvette L. Kasamon

Blood (2014) 124 (21): 680.

https://doi.org/10.1182/blood.V124.21.680.680

Published: 2014

Journal Articles

Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy)

Shannon R. McCurdy, Christopher G. Kanakry, Yvette L. Kasamon, MD, Javier Bolanos Meade, MD, Hua-Ling Tsai, Margaret M. Showel, Jennifer A. Kanakry, Heather J. Symons, MD MHS, Gary L. Rosner, Sc.D, Ephraim J. Fuchs, Richard J. Jones, Leo Luznik, MD

Blood (2014) 124 (21): 730.

https://doi.org/10.1182/blood.V124.21.730.730

Published: 2014

Journal Articles

Outcomes Of Nonmyeloablative (NMA) Haploidentical Blood Or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy) For Lymphoma

Yvette L. Kasamon, Javier Bolaños-Meade, Douglas Gladstone, Lode J. Swinnen, Jennifer A. Kanakry, Hua-Ling Tsai, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder

Blood (2013) 122 (21): 2091.

https://doi.org/10.1182/blood.V122.21.2091.2091

Published: 2013

Journal Articles

Encouraging Outcomes In Older Patients (Pts) Following Nonmyeloablative (NMA) Haploidentical Blood or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy)

Yvette L. Kasamon, Gabrielle Prince, Javier Bolaños-Meade, Hua-Ling Tsai, Leo Luznik, Richard F. Ambinder, Ephraim J. Fuchs, Richard J. Jones

Blood (2013) 122 (21): 158.

https://doi.org/10.1182/blood.V122.21.158.158

Published: 2013

NARROW

A Retrospective Cohort Analysis of Minimal Residual Disease (MRD) across Therapy in FLT3 Acute Myeloid Leukemia (AML)

High Molecular Risk Mutations (HMR) Drive Progression of CALR -mutated Myeloproliferative Neoplasm (MPN)

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Favorable Outcomes for High-Risk MDS and Oligoblastic AML with MDS-Related Changes with Reduced Intensity Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Allogeneic Blood or Marrow Transplantation (alloBMT) Using Haploidentical Grandchildren Donors and Post-Transplant Cyclophosphamide (PTCy) -Based Gvhd Prophylaxis

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

The Presence of SETBP1 , RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN)

The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient

Grade II Acute Gvhd Improves Progression-Free Survival after Myeloablative HLA-Matched Bone Marrow Transplant with Posttransplantation Cyclophosphamide

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy)

Outcomes Of Nonmyeloablative (NMA) Haploidentical Blood Or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy) For Lymphoma

Encouraging Outcomes In Older Patients (Pts) Following Nonmyeloablative (NMA) Haploidentical Blood or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only